Shareholder Rebellion Intensifies as Staar Surgical Acquisition Reaches Critical Juncture
Published on 09/23/2025 at 03:18 | Redaktion boerse-global.de
The proposed acquisition of Staar Surgical by Alcon is approaching a decisive moment, marked by growing dissent from major shareholders. A 45-day “go-shop” period, which concluded on Friday without a superior offer, has failed to quell the opposition. The company’s board continues to champion the deal as value-maximizing, but it now faces significant resistance from two key investors who argue the terms significantly undervalue the company.
The rebellion gained substantial momentum with the formal opposition of Yunqi Capital, an investment firm holding a 5.1% stake. They have aligned with the largest shareholder, Broadwood Partners, which controls 27.4% of the company. Both entities have publicly rejected Alcon’s offer of $28 per share, deeming it an inadequate valuation of Staar Surgical’s worth. Despite... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
